Denosumab, cortical bone and bone erosions in rheumatoid arthritis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. Erythrocyte membrane camouflaged celastrol and bilirubin self-assembly for rheumatoid arthritis immunotherapy based on STING inhibition and RONS clearance.Journal of nanobiotechnology · 2025
   Article
2. Changes in bone turnover markers and bone modulators during abatacept treatment.Scientific reports · 2023
   Observational
3. Personalized Therapeutic Strategies in the Management of Osteoporosis in Patients with Autoantibody-Positive Rheumatoid Arthritis.Journal of clinical medicine · 2022
   Review
4. The Emerging Roles of Endocrine Hormones in Different Arthritic Disorders.Frontiers in endocrinology · 2021
   Review
5. The impact of long-term biologics/target therapy on bone mineral density in rheumatoid arthritis: a propensity score-matched analysis.Rheumatology (Oxford, England) · 2020
   Observational
6. Osteoporosis in Inflammatory Arthritides: New Perspective on Pathogenesis and Treatment.Frontiers in medicine · 2020
   Review
7. Osteoporosis in Rheumatic Diseases.International journal of molecular sciences · 2019
   Review
8. Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates.Journal of experimental orthopaedics · 2019
   Article
9. Bone erosions in rheumatoid arthritis: recent developments in pathogenesis and therapeutic implications.Journal of musculoskeletal & neuronal interactions · 2018
   Review
10. Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2018
    Article
11. Role of LIGHT in the pathogenesis of joint destruction in rheumatoid arthritis.World journal of experimental medicine · 2017
    Article
12. Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis.Expert opinion on biological therapy · 2017
    Review

Corrections and comments

• Commented on by
  Response to: 'Denosumab, cortical bone and bone erosion in rheumatoid arthritis' by Rossini et al.2016
• Comment on
  Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial.2016

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as